Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples